Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Recruiting 4Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Non-squamous Non-small-cell Lung Cancer 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Tumors 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

Irinotecan 58Bevacizumab 56Oxaliplatin 49Leucovorin 49Fluorouracil 49Capecitabine 45Cetuximab 44pembrolizumab 23IFL protocol 15Nivolumab 11regorafenib 10Panitumumab 10Celecoxib 8Radiotherapy 7Cyclophosphamide 7atezolizumab 6Surgical Procedures, Operative 6Gemcitabine 6Folfox protocol 6Colonoscopy 6trifluridine tipiracil drug combination 5Neoadjuvant Therapy 5Metformin 5Immunohistochemistry 5Biopsy 5tislelizumab 4spartalizumab 4durvalumab 4Trastuzumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colorectal Neoplasms × camrelizumab × Clear all
NCT03645876 2019-05-10

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
12 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡